{"filing":{"accession_number":"0001062993-26-004806","cik":"0001997296","ticker":"MDCXW","company_name":"Medicus Pharma Ltd.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-02","primary_document":"form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/form8k.htm"},"events":[{"id":31479,"run_id":28886,"accession_number":"0001062993-26-004806","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Medicus Pharma entered into a Co-Development and License Agreement with Pfizer on September 2, 2026, granting an exclusive, worldwide license to develop and commercialize CD228V, an early-stage antibody-drug conjugate. The transaction involves a $12.0 million upfront payment, $15.0 million deferred payment, potential milestone payments exceeding $1.0 billion, and royalties on net sales. This constitutes a material strategic transaction involving acquisition of intellectual property rights and a significant financial commitment that would materially affect a reasonable investor's assessment of the company's pipeline and financial obligations.","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34374,"accession_number":"0001062993-26-004806","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Medicus Pharma entered into a Co-Development and License Agreement with Pfizer on September 2, 2026, granting an exclusive, worldwide license to develop and commercialize CD228V, an early-stage antibody-drug conjugate. The transaction involves a $12.0 million upfront payment, $15.0 million deferred payment, potential milestone payments exceeding $1.0 billion, and royalties on net sales. This constitutes a material strategic transaction involving acquisition of intellectual property rights and a significant financial commitment that would materially affect a reasonable investor's assessment of the company's pipeline and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:02:10.699903+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34374,"accession_number":"0001062993-26-004806","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Medicus Pharma entered into a Co-Development and License Agreement with Pfizer on September 2, 2026, granting an exclusive, worldwide license to develop and commercialize CD228V, an early-stage antibody-drug conjugate. The transaction involves a $12.0 million upfront payment, $15.0 million deferred payment, potential milestone payments exceeding $1.0 billion, and royalties on net sales. This constitutes a material strategic transaction involving acquisition of intellectual property rights and a significant financial commitment that would materially affect a reasonable investor's assessment of the company's pipeline and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:02:10.699903+00:00","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-09-03"}]}